Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30696861 | 0.89 | PLA2G4B (0.61) | PLA2G4BHDAC8GGPS1HDAC1HDAC2 | |
| SCHEMBL22326323 | 0.85 | PLA2G4B (0.55) | PLA2G4BHDAC8CNR1CNR2KDM4E | |
| SCHEMBL31457831 | 0.84 | PLA2G4B (0.51) | PLA2G4BKDM4EALDH1A1GAAGGPS1 | |
| SCHEMBL14987498 | 0.84 | SLC7A5 (0.45) | PLA2G4BALDH1A1GAAPOLB | |
| SCHEMBL25082081 | 0.83 | PLA2G4B (0.48) | PLA2G4BKDM4EGGPS1POLB | |
| SCHEMBL30278822 | 0.83 | PLA2G4B (0.48) | PLA2G4BKDM4EGGPS1POLB | |
| SCHEMBL31457778 | 0.83 | PLA2G4B (0.50) | PLA2G4BKDM4EALDH1A1GAAGGPS1 | |
| SCHEMBL22326247 | 0.82 | KDM4E (0.43) | PLA2G4BKDM4EALDH1A1GAAPOLB | |
| SCHEMBL3980344 | 0.82 | CA12 (0.52) | KDM4EALDH1A1GAA | |
| SCHEMBL9402581 | 0.82 | PLA2G4B (0.64) | PLA2G4BCNR1CNR2GGPS1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-04-07 | — | — | US | disclosed |
| EP-3922632-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020162725-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | EED, VHL, CUL1 | PLA2G4B 3549/4885HDAC8 1435/4885CNR1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.